Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Leen Vijgen"'
Autor:
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Publikováno v:
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhoti
Externí odkaz:
https://doaj.org/article/61e6a0119abd4699b62cba409899ce21
Publikováno v:
Virology Journal, Vol 14, Iss 1, Pp 1-10 (2017)
Abstract Background In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high su
Externí odkaz:
https://doaj.org/article/b8e56cc302c3411a9f7452c4760b97dc
Autor:
Matthew W McClure, Elina Berliba, Tengiz Tsertsvadze, Adrian Streinu-Cercel, Leen Vijgen, Béatrice Astruc, Alain Patat, Christopher Westland, Sushmita Chanda, Qingling Zhang, Thomas N Kakuda, Jennifer Vuong, Nick Khorlin, Leonid Beigelman, Lawrence M Blatt, John Fry
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204974 (2018)
BACKGROUND:The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection. METHODS:This three-part randomized, double-blind study evaluated the safe
Externí odkaz:
https://doaj.org/article/734ab2d56f1a434cbd65736ecb72aa86
Autor:
Yasuhiro Asahina, Toshikazu Nakano, Hiroshi Yatsuhashi, Yosuke Hagiwara, Tetsuo Takehara, Yuhan Huang, Hiroko Shimizu, Leen Vijgen, Yasuhito Tanaka, Masayuki Kurosaki, Naoki Hiramatsu, Akito Nozaki, Kazuaki Chayama, Norio Hayashi, Hiroki Yoshida, Naoya Sakamoto, Michael Biermer
Publikováno v:
Journal of Gastroenterology
Background The efficacy, safety, and pharmacokinetics of the combination of three direct-acting antiviral (DAA) agents (adafosbuvir [also known as AL-335], odalasvir, and simeprevir) were investigated in DAA treatment-naïve Japanese patients with ge
Autor:
Matthew W. McClure, Christian Schwabe, Thomas N. Kakuda, Lawrence M. Blatt, John Fry, Edward Gane, Catherine A.M. Stedman, Leen Vijgen, Sushmita Mukherjee Chanda
Publikováno v:
Hepatology. 68:2145-2157
This open-label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct-acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6-12-week oral regimens of 400-800 mg once daily
Autor:
M. Gamil, Ann Vandevoorde, Veerle Van Eygen, Pieter Van Remoortere, Fred Poordad, Donghan Luo, Eric Lawitz, Julio A. Gutierrez, Greet Beets, Leen Vijgen, Maria Beumont
Publikováno v:
Health Science Reports
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhotic patient
Autor:
Sivi Ouwerkerk-Mahadevan, Eric Lawitz, Thomas N. Kakuda, Maria Beumont, Mark S. Sulkowski, O. Khalid, William B. Smith, V. Van Eygen, Leen Vijgen, R. Ghalib, Jordan J. Feld, P. Van Remoortere, M. Gamil, A. Corregidor, Donghan Luo, Franco Felizarta
Publikováno v:
Journal of Viral Hepatitis. 25:631-639
The phase 2, open-label ACCORDION (ClinicalTrials.gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C
Autor:
Leen Vijgen, Lotke Tambuyzer, Bart Stoops, Sophie Lachau-Durand, Abdellah Tahri, Laurent Leclercq, Tse-I Lin, Jan Snoeys, Kenny Simmen, Jan Martin Berke, Tim H. M. Jonckers, Pierre Jean-Marie Bernard Raboisson
Publikováno v:
Journal of Medicinal Chemistry. 59:5790-5798
JNJ-54257099 (9) is a novel cyclic phosphate ester derivative that belongs to the class of 2′-deoxy-2′-spirooxetane uridine nucleotide prodrugs which are known as inhibitors of the HCV NS5B RNA-dependent RNA polymerase (RdRp). In the Huh-7 HCV ge
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:7548-7557
Simeprevir (TMC435) is a once-daily, single-pill, oral hepatitis C virus (HCV) NS3 protease inhibitor approved for the treatment of chronic HCV infection. Phenotypic characterization of baseline isolates and isolates from HCV genotype 1-infected pati
Autor:
Elina Berliba, Alain Patat, Jennifer Vuong, Béatrice Astruc, Matthew W. McClure, John Fry, Leen Vijgen, Thomas N. Kakuda, Lawrence M. Blatt, Tengiz Tsertsvadze, Nick Khorlin, Adrian Streinu-Cercel, Sushmita Mukherjee Chanda, Christopher Westland, Qingling Zhang, Leonid Beigelman
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204974 (2018)
PLoS ONE
PLoS ONE
Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection. Methods This three-part randomized, double-blind study evaluated the safe